Literature DB >> 25673822

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Marieke Aarts1, Ilirjana Bajrami1, Maria T Herrera-Abreu1, Richard Elliott1, Rachel Brough1, Alan Ashworth1, Christopher J Lord1, Nicholas C Turner2.   

Abstract

WEE1 kinase regulates CDK1 and CDK2 activity to facilitate DNA replication during S-phase and to prevent unscheduled entry into mitosis. WEE1 inhibitors synergize with DNA-damaging agents that arrest cells in S-phase by triggering direct mitotic entry without completing DNA synthesis, resulting in catastrophic chromosome fragmentation and apoptosis. Here, we investigated how WEE1 inhibition could be best exploited for cancer therapy by performing a functional genetic screen to identify novel determinants of sensitivity to WEE1 inhibition. Inhibition of kinases that regulate CDK activity, CHK1 and MYT1, synergized with WEE1 inhibition through both increased replication stress and forced mitotic entry of S-phase cells. Loss of multiple components of the Fanconi anemia (FA) and homologous recombination (HR) pathways, in particular DNA helicases, sensitized to WEE1 inhibition. Silencing of FA/HR genes resulted in excessive replication stress and nucleotide depletion following WEE1 inhibition, which ultimately led to increased unscheduled mitotic entry. Our results suggest that cancers with defects in FA and HR pathways may be targeted by WEE1 inhibition, providing a basis for a novel synthetic lethal strategy for cancers harboring FA/HR defects. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25673822      PMCID: PMC6485454          DOI: 10.1158/1535-7163.MCT-14-0845

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

2.  Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase.

Authors:  Easwari Kumaraswamy; Ramin Shiekhattar
Journal:  Mol Cell Biol       Date:  2007-07-30       Impact factor: 4.272

3.  ATR activation and replication fork restart are defective in FANCM-deficient cells.

Authors:  Rebekka A Schwab; Andrew N Blackford; Wojciech Niedzwiedz
Journal:  EMBO J       Date:  2010-01-07       Impact factor: 11.598

4.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.

Authors:  Hiroshi Hirai; Yoshikazu Iwasawa; Megumu Okada; Tsuyoshi Arai; Toshihide Nishibata; Makiko Kobayashi; Toshifumi Kimura; Naoki Kaneko; Junko Ohtani; Kazunori Yamanaka; Hiraku Itadani; Ikuko Takahashi-Suzuki; Kazuhiro Fukasawa; Hiroko Oki; Tadahiro Nambu; Jian Jiang; Takumi Sakai; Hiroharu Arakawa; Toshihiro Sakamoto; Takeshi Sagara; Takashi Yoshizumi; Shinji Mizuarai; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

5.  Differential contributions of mammalian Rad54 paralogs to recombination, DNA damage repair, and meiosis.

Authors:  Joanna Wesoly; Sheba Agarwal; Stefan Sigurdsson; Wendy Bussen; Stephen Van Komen; Jian Qin; Harry van Steeg; Jan van Benthem; Evelyne Wassenaar; Willy M Baarends; Mehrnaz Ghazvini; Agnieszka A Tafel; Helen Heath; Niels Galjart; Jeroen Essers; J Anton Grootegoed; Norman Arnheim; Olga Bezzubova; Jean-Marie Buerstedde; Patrick Sung; Roland Kanaar
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

6.  Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase.

Authors:  L L Parker; H Piwnica-Worms
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

7.  MCM10 mediates RECQ4 association with MCM2-7 helicase complex during DNA replication.

Authors:  Xiaohua Xu; Patrick J Rochette; Eminet A Feyissa; Tina V Su; Yilun Liu
Journal:  EMBO J       Date:  2009-08-20       Impact factor: 11.598

8.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

Review 10.  The decision to enter mitosis: feedback and redundancy in the mitotic entry network.

Authors:  Arne Lindqvist; Verónica Rodríguez-Bravo; René H Medema
Journal:  J Cell Biol       Date:  2009-04-13       Impact factor: 10.539

View more
  31 in total

1.  PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Authors:  Andrä Brunner; Aldwin Suryo Rahmanto; Henrik Johansson; Marcela Franco; Johanna Viiliäinen; Mohiuddin Gazi; Oliver Frings; Erik Fredlund; Charles Spruck; Janne Lehtiö; Juha K Rantala; Lars-Gunnar Larsson; Olle Sangfelt
Journal:  Elife       Date:  2020-07-06       Impact factor: 8.140

2.  The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.

Authors:  Leslie A Parsels; Joshua D Parsels; Daria M Tanska; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

3.  Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.

Authors:  Ahmed Diab; Michael Kao; Keffy Kehrli; Hee Yeon Kim; Julia Sidorova; Eduardo Mendez
Journal:  Mol Cancer Res       Date:  2019-01-24       Impact factor: 5.852

4.  Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Authors:  Suzanne Leijen; Robin M J M van Geel; Anna C Pavlick; Raoul Tibes; Lee Rosen; Albiruni R Abdul Razak; Raymond Lam; Tim Demuth; Shelonitda Rose; Mark A Lee; Tomoko Freshwater; Stuart Shumway; Li Wen Liang; Amit M Oza; Jan H M Schellens; Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.

Authors:  Leslie A Parsels; David Karnak; Joshua D Parsels; Qiang Zhang; Jonathan Vélez-Padilla; Zachery R Reichert; Daniel R Wahl; Jonathan Maybaum; Mark J O'Connor; Theodore S Lawrence; Meredith A Morgan
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

6.  Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.

Authors:  Leslie A Parsels; Daria M Tanska; Joshua D Parsels; Sonya D Zabludoff; Kyle C Cuneo; Theodore S Lawrence; Jonathan Maybaum; Meredith A Morgan
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.

Authors:  G Chen; B Zhang; H Xu; Y Sun; Y Shi; Y Luo; H Jia; F Wang
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

8.  FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.

Authors:  Ahmed Diab; Hakan Gem; Jherek Swanger; Hee Yeon Kim; Kaleb Smith; Grace Zou; Sharat Raju; Michael Kao; Matthew Fitzgibbon; Keith R Loeb; Cristina P Rodriguez; Eduardo Méndez; Denise A Galloway; Julia M Sidorova; Bruce E Clurman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-22       Impact factor: 11.205

Review 9.  Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics.

Authors:  Lydia Robinson-Garcia; Joana Ferreira da Silva; Joanna I Loizou
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

10.  Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

Authors:  Arielle L Heeke; Joanne Xiu; Andrew Elliott; W Michael Korn; Filipa Lynce; Paula R Pohlmann; Claudine Isaacs; Sandra M Swain; Gregory Vidal; Lee S Schwartzberg; Antoinette R Tan
Journal:  Breast Cancer Res Treat       Date:  2020-08-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.